Brilacidin (PMX-30063) is a synthetic, non-peptide, defensin-mimetic compound, exhibits broad-spectrum anti-microbial and anti-SARS-CoV-2 activities.
Brilacidin at 0.5-1 µM has potent bactericidal activities against Gram-positive and Gram-negative bacteria, with minimal propensity for the development of resistance, causes membrane depolarization in Staphylococcus aureus (Gram-positive).
Brilacidin inhibits SARS-CoV-2 viral infection by blocking viral entry, inhibits pseudotyped SARS-CoV-2 viruses expressing spike proteins from the P.1 Brazil strain and the B.1.1.7 UK strain.
